Transcat, Inc.

NASDAQ:TRNS

Industrial - Distribution

Industrials
$100.12 +2.19%

+$2.00 today

Market cap
$941.61M
Beta
0.70
P/E (TTM)
150.2
EPS (TTM)
$0.62
52W Low $50.23High $94.76

Volume 0.11M

Average 0.16M

TRNS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Transcat, Inc.NASDAQ: TRNS

Stock-Based Compensation · Q4 FY2025 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q4 FY2025 stock-based compensation of $679K fell 42.1% year over year, behind the +132.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 82.6% from the prior quarter. Over 3 fiscal years it compounded at +30.8% a year.

Context

  • Stock-based compensation amounted to 2.3% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -42.1% toward the trailing-twelve-month pace of +132.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$679K-82.6% QoQ
Last fiscal yearMar 2026
$7.55M+132.4% YoY
LTMMar 2026
$7.55M+132.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.1%——
1 year+132.4%——
3-year CAGR+30.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
7.55M USD
Year-over-year change
+132.4%
4-year CAGR
+34.2%

Stock-Based Compensation vs competitors

How TRNS compares with its peers on the latest reported figures

  • TRNS's LTM Mar 2026 stock-based compensation of $7.55M is the 10th largest of the 11 companies compared; the peer median is $25.56M.
  • Its year-over-year change of +132.4% is the highest of 11, against a peer median of -1.9%.
  • Stock-based compensation amounts to 2.3% of revenue for TRNS, versus a peer median of 2.6%.
TRNS Competitors Peer median
Stock-Based Compensation for TRNS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$45.8M +43.1%-1.6%1.8%
TECHBio-Techne CorporationLTM Sep 2026$43.09M +56.0%+1.8%3.5%
QDELQuidelOrtho CorporationLTM Mar 2026$34.2M -23.5%-1.8%1.3%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
LABStandard BioTools Inc.LTM Mar 2026$27.48M -5.7%+25.8%31.9%
BLFSBioLife Solutions, Inc.LTM Mar 2026$23.65M -18.2%-3.2%23.7%
MTDMettler-Toledo International Inc.LTM Jun 2026$22.83M +7.5%+4.6%0.6%
TICTIC Solutions, Inc.LTM Jun 2026$19.21M -71.7%+88.5%0.9%
UFPTUFP Technologies, Inc.LTM Jun 2026$10.31M +27.5%+40.3%1.6%
TRNSTranscat, Inc.LTM Mar 2026$7.55M +132.4%+30.8%2.3%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.42M +1.9%-2.6%5.8%
Peer median (excluding TRNS) $25.56M-1.9%+3.2%2.6%

Competitors are the stored peer set for TRNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income11.38M10.69M13.65M14.52M5.38M
Depreciation & Amortization9.57M10.96M13.54M18.57M26.17M
Deferred Income Tax559K(186K)(1.6M)(5K)827K
Stock-Based Compensation2.33M3.38M4.51M3.25M7.55M
Change in Working Capital(6.34M)(8.05M)2.05M3.21M(11.9M)
Accounts Receivables(3.39M)74K406K(1.29M)(6.58M)
Inventory(122K)(3.38M)2.32M4.39M839K
Accounts Payables1.9M1.6M(5.01M)4.94M965K
Other Working Capital(4.73M)(6.34M)4.33M(4.83M)(7.13M)
Other Non-Cash Items122K162K459K(550K)6.83M
Operating Cash Flow17.62M16.95M32.62M38.99M34.85M
Capital Expenditures(10.15M)(9.41M)(13.28M)(13.2M)(15.3M)
Acquisitions (Net)(29.81M)(9.11M)(12.86M)(87.44M)(82.53M)
Purchases of Investments00(15.53M)00
Sales of Investments00000
Other Investing Activities109K10K016.63M0
Investing Cash Flow(39.85M)(18.51M)(41.67M)(84M)(97.82M)
Debt Repayment28.89M665K(44.96M)28.55M66.41M
Common Stock Issued1.49M658K77.27M1.87M842K
Common Stock Repurchased(6.68M)(447K)(4.91M)(3.57M)(469K)
Dividends Paid00000
Other Financing Activities0000(280K)
Financing Cash Flow23.69M876K27.4M26.86M66.5M
Effect of Forex Changes(625K)821K(228K)24K(103K)
Net Change in Cash836K135K18.12M(18.13M)3.43M
Free Cash Flow7.47M7.54M19.34M25.79M19.55M

Transcat, Inc.

NASDAQ:TRNS

Intrinsic Alpha fair value

Locked

Current Price

$100.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.